Shawn W. Sun

930 total citations · 1 hit paper
8 papers, 660 citations indexed

About

Shawn W. Sun is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Shawn W. Sun has authored 8 papers receiving a total of 660 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 2 papers in Cancer Research. Recurrent topics in Shawn W. Sun's work include Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (3 papers) and CAR-T cell therapy research (2 papers). Shawn W. Sun is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (3 papers) and CAR-T cell therapy research (2 papers). Shawn W. Sun collaborates with scholars based in United States, Japan and Switzerland. Shawn W. Sun's co-authors include Tien Hoang, Daniil Stroyakovskiy, Federico Cappuzzo, Henry Jacob Conter, Toshiyuki Kozuki, Mark A. Socinski, Delvys Rodríguez‐Abreu, Vilma Graupner, Ihor Vynnychenko and Robert M. Jotte and has published in prestigious journals such as Journal of Clinical Oncology, Current Opinion in Chemical Biology and Journal of Thoracic Oncology.

In The Last Decade

Shawn W. Sun

8 papers receiving 655 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

2020 405 citations Robert M. Jotte, Federico Cappuzzo et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by Shawn W. Sun

Since Specialization

Citations

This map shows the geographic impact of Shawn W. Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shawn W. Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shawn W. Sun more than expected).

Fields of papers citing papers by Shawn W. Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shawn W. Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shawn W. Sun. The network helps show where Shawn W. Sun may publish in the future.

Co-authorship network of co-authors of Shawn W. Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Shawn W. Sun. A scholar is included among the top collaborators of Shawn W. Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shawn W. Sun. Shawn W. Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer 2024 ·Future Oncology ·Sara M. Tolaney, Angela DeMichele, Toshimi Takano, Hope S. Rugo, Charles M. Perou, Filipa Lynce, Heather A. Parsons, Cesar Augusto Santa-Maria, Gabrielle B. Rocque, Wenliang Yao, Shawn W. Sun, Simonetta Mocci, Ann H. Partridge, Lisa A. Carey	10
2	ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery. 2023 ·Journal of Clinical Oncology ·Sara M. Tolaney, Angela DeMichele, Toshimi Takano, Hope S. Rugo, Charles M. Perou, Otto Metzger, Heather A. Parsons, Cesar Augusto Santa-Maria, Gabrielle B. Rocque, Wenliang Yao, Shawn W. Sun, Simonetta Mocci, Ann H. Partridge, Lisa A. Carey	11
3	Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice 2022 ·JTO Clinical and Research Reports ·Anjali Saqi, Kevin O. Leslie, André L. Moreira, Sylvie Lantuéjoul, Catherine A. Shu, Naiyer A. Rizvi, Joshua Sonett, Kosei Tajima, Shawn W. Sun, Barbara J. Gitlitz, Thomas V. Colby	17
4	Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC 2021 ·JTO Clinical and Research Reports ·Jay M. Lee, Anthony W. Kim, Tomasz Marjański, Pierre‐Emmanuel Falcoz, Masahiro Tsuboi, (unknown), Shawn W. Sun, Barbara J. Gitlitz	21
5	Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial breakdown → 2020 ·Journal of Thoracic Oncology ·Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Maen Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, (unknown), Vilma Graupner, Shawn W. Sun, Tien Hoang, Helen Jessop, Mark L. McCleland, Marcus Ballinger, Alan Sandler, Mark A. Socinski	405
6	P2.17-27 IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy 2018 ·Journal of Thoracic Oncology ·Naiyer A. Rizvi, David R. Gandara, Benjamin Solomon, (unknown), Alessandro Brunelli, Shawn W. Sun, Barbara J. Gitlitz, Kosei Tajima, Wei-Chun Lin, A. Sandler, Solange Peters	7
7	Recent progress in therapeutic antibodies for cancer immunotherapy 2018 ·Current Opinion in Chemical Biology ·Anthony Lee, Shawn W. Sun, Alan N. Sandler, Tien Hoang	19
8	IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. 2018 ·Journal of Clinical Oncology ·Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Maen Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, Carlos Alberto da Silva, Vilma Graupner, Shawn W. Sun, Ray Lin, (unknown), Marcin Kowanetz, Tien Hoang, Alan N. Sandler, Mark A. Socinski	170

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact